Fiche centre
Center for Rare Neurological Diseases
Norcross — United States
Essais liés4clinical trials
VilleNorcrosslocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05076838
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Diazepam Nasal Spray [Valtoco] | Épilepsie | Phase 1/2 | NCT05076838 | Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy | COMPLETED |
| TAK-935 | Épilepsie | Phase 2 | NCT03650452 | ELEKTRA — A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies | COMPLETED |
| Soticlestat | Épilepsie | Phase 2 | NCT03635073 | Endymion 1 — A Study of Soticlestat in Adults and Children With Rare Epilepsies | TERMINATED |
| Soticlestat | Épilepsie | Phase 2 | NCT03694275 | A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY) | COMPLETED |